Home » Business News » 2013 » February » February 8, 2013

MorphoSys Receives First Patent on Novel Antibody Platform Ylanthia in the US

February 8, 2013 - Martinsried, Germany And Munich, Germany

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) today announced that theUS Patent and Trademark Office (USPTO) has granted the first patentcovering theCompany's latest antibody platform Ylanthia, which became commerciallyavailablefor existing and new partners in 2012.

"A growing patent portfolio on our new antibody platform Ylanthiais animportant factor for a successful partnering process in our corelicensingmarkets, which we intend to intensify during the course of 2013",commented Dr.Marlies Sproll, Chief Scientific Officer of MorphoSys AG.

The new patent (US 8,367,586) covers the composition of MorphoSys'sYlanthiaantibody library. Ylanthia comprises more than 100 billion distinct, fullyhumanantibodies, which makes it the industry's largest known antibody Fablibrary. Ituses 36 fixed, naturally-occurring heavy and light chain frameworkcombinations,which translates into unprecedented structural diversity. Thelibrary'sdiversity is expected to result in antibodies against previouslyinaccessibletarget molecules and unique epitope coverage.

Ylanthia's antibody frameworks were pre-selected for expressionlevels,stability and aggregation behavior. A shift towards higher stability andstresstolerance will increase shelf life and serum stability of resultingantibodyproducts, making them more cost-effective to produce and administer. Ahighersolubility in turn opens up the path for more convenient ways ofadministration,to the benefit of patients. When needed, antibodies from the Ylanthialibraryare optimized using MorphoSys's proprietary Slonomics technology.Slonomicsenables optimization of Ylanthia antibodies with unprecedented speedandflexibility.

About MorphoSys:

MorphoSys developed HuCAL, the most successful antibody library technologyinthe pharmaceutical industry. By successfully applying this and otherpatentedtechnologies, MorphoSys has become a leader in the field of therapeuticantibodies, one of the fastest-growing drug classes in human healthcare.Together with its pharmaceutical partners, MorphoSys has built atherapeuticpipeline of more than 70 human antibody drug candidates for the treatmentofcancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few.Withits ongoing commitment to new antibody technology and drug development,MorphoSys is focused on making the healthcare products of tomorrow.MorphoSys islisted on the Frankfurt Stock Exchange under the symbol MOR. For regularupdatesabout MorphoSys, visit

HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®,RapMAT®, arYla®,Ylanthia® and 100 billion high potentials® are registeredtrademarks ofMorphoSys AG.

Slonomics(®) is a registered trademark of Sloning BioTechnologyGmbH, asubsidiary of MorphoSys AG.

This communication contains certain forward-looking statementsconcerning theMorphoSys group of companies. The forward-looking statements containedhereinrepresent the judgment of MorphoSys as of the date of this release andinvolverisks and uncertainties. Should actual conditions differ from theCompany'sassumptions, actual results and actions may differ from thoseanticipated.MorphoSys does not intend to update any of these forward-lookingstatements asfar as the wording of the relevant press release is concerned.

Media Release (PDF):

This announcement is distributed by Thomson Reuters on behalf ofThomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: MorphoSys AG via Thomson Reuters ONE


For more information, please contact:

MorphoSys AG
Dr. Claudia Gutjahr-Loser
Head of Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-122

Mario Brkulj
Associate Director Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-454

Alexandra Goller
Specialist Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-332

Email Contact


Comment on this story